JMP Securities Increases BioCryst Pharmaceuticals (NASDAQ:BCRX) Price Target to $15.00

BioCryst Pharmaceuticals (NASDAQ:BCRX) had its target price boosted by JMP Securities from $14.00 to $15.00 in a research report released on Tuesday, Benzinga reports. JMP Securities currently has a market outperform rating on the biotechnology company’s stock.

Other analysts also recently issued reports about the company. Needham & Company LLC reiterated a buy rating and set a $12.00 target price on shares of BioCryst Pharmaceuticals in a research report on Tuesday. HC Wainwright reiterated a buy rating and set a $30.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of Moderate Buy and an average price target of $14.00.

BioCryst Pharmaceuticals Stock Performance

BCRX stock opened at $5.34 on Tuesday. BioCryst Pharmaceuticals has a one year low of $4.03 and a one year high of $8.96. The company has a fifty day moving average of $4.89 and a 200-day moving average of $5.45. The stock has a market capitalization of $1.10 billion, a PE ratio of -4.99 and a beta of 1.96.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its earnings results on Monday, May 6th. The biotechnology company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.06. The company had revenue of $92.80 million for the quarter, compared to analysts’ expectations of $85.62 million. BioCryst Pharmaceuticals’s revenue for the quarter was up 34.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.28) earnings per share. Equities analysts forecast that BioCryst Pharmaceuticals will post -0.69 earnings per share for the current fiscal year.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. Fifth Third Bancorp boosted its holdings in BioCryst Pharmaceuticals by 17,500.0% in the third quarter. Fifth Third Bancorp now owns 3,520 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 3,500 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in shares of BioCryst Pharmaceuticals by 96.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 4,865 shares of the biotechnology company’s stock valued at $34,000 after purchasing an additional 2,388 shares in the last quarter. Quarry LP purchased a new stake in shares of BioCryst Pharmaceuticals during the 4th quarter worth about $54,000. Tower Research Capital LLC TRC increased its position in BioCryst Pharmaceuticals by 131.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 10,420 shares of the biotechnology company’s stock worth $62,000 after purchasing an additional 5,912 shares in the last quarter. Finally, JGP Global Gestao de Recursos Ltda. purchased a new position in BioCryst Pharmaceuticals in the fourth quarter valued at approximately $64,000. Institutional investors and hedge funds own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.